ReferencesPackage Insert: http://us.gsk.com/products/assets/us_raxibacumab.pdf
1. Nabel G. Protecting against future shock--inhalational anthrax. N Engl J Med. 2009 Jul 9;361(2):191-3.
http://www.ncbi.nlm.nih.gov/pubmed/19587345
2. Migone T-S, Subramanian G, Zhong J, Healey L, Corey A, Devalaraja M, et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med. 2009 Jul 9;361(2):135-44. http://www.ncbi.nlm.nih.gov/pubmed/19587338
3. Goldenberg M. Pharmaceutical approval update. P & T: a peer-reviewed journal for formulary management. 2013;38(2):86-95.
http://www.ncbi.nlm.nih.gov/pubmed/23599674
4. Migone TS, Bolmer S, Zhong J, Corey A, Vasconcelos D, Buccellato M, Meister G. Added Benefit of Raxibacumab to Antibiotic Treatment of Inhalational Anthrax. Antimicrob Agents Chemother. 2014 Dec 8. http://www.ncbi.nlm.nih.gov/pubmed/25487792
5. Kummerfeldt CE. Raxibacumab: potential role in the treatment of inhalational anthrax. Infect Drug Resist. 2014 Apr 29;7:101-9. http://www.ncbi.nlm.nih.gov/pubmed/24812521
6. Tsai CW, Morris S. Approval of Raxibacumab for the Treatment of Inhalation Anthrax Under the US Food and Drug Administration "Animal Rule". Front Microbiol. 2015 Dec 1;6:1320. http://www.ncbi.nlm.nih.gov/pubmed/26648915
7. Huang E, Pillai SK, Bower WA, Hendricks KA, Guarnizo JT et al. Antitoxin Treatment of Inhalation Anthrax: A Systematic Review. Health Secur. 2015 Nov-Dec;13(6):365-77. https://www.ncbi.nlm.nih.gov/pubmed/26690378